BeOne Medicines AG (ONC)
| Market Cap | 35.73B |
| Revenue (ttm) | 4.97B |
| Net Income (ttm) | 68.55M |
| Shares Out | 110.66M |
| EPS (ttm) | 0.58 |
| PE Ratio | 521.25 |
| Forward PE | 71.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 603,795 |
| Open | 332.64 |
| Previous Close | 331.40 |
| Day's Range | 310.11 - 332.64 |
| 52-Week Range | 170.99 - 385.22 |
| Beta | 0.46 |
| Analysts | Strong Buy |
| Price Target | 369.50 (+14.43%) |
| Earnings Date | Nov 6, 2025 |
About ONC
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as... [Read more]
Financial Performance
In 2024, BeOne Medicines AG's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for ONC stock is "Strong Buy." The 12-month stock price target is $369.5, which is an increase of 14.43% from the latest price.
News
BeOne Medicines Continues To Execute In Q3
BeOne Medicines maintains Strong Buy as Brukinsa and Tevimbra drive robust growth and pipeline catalysts approach. Q3 2025 marked a pivotal inflection point with 41% YoY sales growth and positive earn...
Artisan International Small-Mid Fund Q3 2025 Performance Review
Security selection in industrials and a notable overweight to the software industry within information technology were the key detractors from relative returns. Health care is among the three weakest ...
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration...
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, advances its vision to become the world's leading oncology...
BeOne Medicines AG (ONC) Presents at Jefferies London Healthcare Conference 2025 Transcript
BeOne Medicines AG ( ONC) Jefferies London Healthcare Conference 2025 November 17, 2025 11:00 AM EST Company Participants John Oyler - Co-Founder, Executive Chairman & CEO Aaron Rosenberg - Chief Fin...
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3...
BeOne Medicines AG (ONC) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
BeOne Medicines AG ( ONC) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 9:30 AM EST Company Participants Aaron Rosenberg - Chief Financial Officer John Scotti Co...
BeOne Medicines AG (ONC) Q3 2025 Earnings Call Transcript
BeOne Medicines AG ( ONC) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Daniel Maller John Oyler - Co-Founder, Executive Chairman & CEO Aaron Rosenberg - Chief Financial Off...
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates fr...
BeOne Medicines to Present at Upcoming Investor Conferences
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in fireside chats at t...
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2025 financial results on Th...
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of data from two pivotal ...
BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology Pipeline
BeOne Medicines AG earns a Strong Buy rating, driven by robust growth of BTK inhibitor BRUKINSA and pipeline progress. BRUKINSA posted 49% year-over-year Q2 2025 revenue growth to $950 million, solidi...
BeOne Medicines' Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration...
BeOne Medicines AG (ONC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
BeOne Medicines AG (NASDAQ:ONC) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:50 PM EDT Company Participants Matt Shaulis - General Manager of North America Mark Lanasa ...
BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients
BeOne Medicines Ltd. ONC (formerly BeiGene) on Friday released topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, an investigational BCL2 inhibitor, in adult patients with relapsed...
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 ...
European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has appr...
BeOne Medicines: Brukinsa's Leadership And Royalty Sale Signal A Stronger Future
BeOne's BRUKINSA has become the market leader in liquid cancers, driving strong revenue growth and solidifying its investment case. Legal risks have diminished, with key patent challenges resolved and...
BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley ...
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it has entered into an agreement to sell i...
European Commission Approves Tablet Formulation of BeOne Medicines' BRUKINSA® for All Approved Indications
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved ...
BeOne Medicines (ONC) Q2 EPS Soars 924%
BeOne Medicines (ONC) Q2 EPS Soars 924%
BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call Transcript
BeOne Medicines Ltd. (NASDAQ:ONC) Q2 2025 Earnings Call August 6, 2025 8:00 AM ET Company Participants Aaron Rosenberg - Chief Financial Officer Daniel Maller - Head of Investor Relations John V.
BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates fr...